Prostate Cancer (PC) is the most common cancer in men and the second leading cancer-related killer behind lung cancer. Prostate Cancer is a malignant adenocarcinoma that typically grows as small tumors in different areas of the gland. If prostate cancer is detected and treated prior to spreading, 10-yr survival is over 90%. Treating prostate cancer is challenging because many tumors are indolent, not requiring treatment, while other tumors are aggressive and life threatening. Currently, there is no diagnostic to predict tumor aggressiveness.
Regardless of initial management, some men will present with or develop advanced disease that requires treatment. Androgen depletion therapy is the standard treatment for prostate cancer that has advanced. When this fails, Taxotere® is the chemotherapy that has shown increased overall survival. In the past two years, five new drugs have been approved for use in advanced PC -- expanding the prostate cancer market and dramatically changing patient management options.
To better understand the intricacies of treating both initial and advanced prostate cancer and the inherent opportunities, Drug Market Info® is pleased to offer Prostate Cancer Market Info™, a comprehensive market assessment, providing a thorough disease and treatment overview by cancer stage, the current value of the market, and a pipeline assessment. Prostate Cancer Market Info™ has been reviewed by a leading clinician and researcher in the field. Most importantly, patients’ insights and in-depth views on disease management and treatment are woven throughout the report which provides a unique understanding of prostate cancer and the unmet needs in the market.
It’s as easy as one, two, three with our Prostate Cancer Market Info report. Insights on patients, doctors, treatment and market value are presented in an easy-to-follow format with current and fully referenced data.
Section One: Patients – Understanding Prostate Cancer: Focuses on PC staging, epidemiology, detection and diagnosis. Includes a discussion of PSA screening and its impact on disease, along with Key Issues and patient insights.
Section Two: Perspectives – Prostate Cancer Management: Provides an overview of therapeutic modalities and treatment options by cancer stage. Brand and treatment comparisons, along with patients’ perspectives, experiences and insights offer an in-depth overview of how Prostate Cancer is managed.
Section Three: Potential – Prostate Cancer Market: Provides overall Prostate Cancer market value and the contribution by treatment modality, along with 5-year sales and unit trend analyses. Leading companies and brands, along with new product performance and current pricing are also profiled. The unique PC clinical trial environment, pipeline target overview and late-stage pipeline are included.
Summary: The major take-aways from the presentation, including “What Makes the PC Market Attractive,” Seven Most Important Facts About PC” and information about ZERO - The Project to End Prostate Cancer concludes the report.
